Daniel Kofi Nyame
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Kofi Nyame has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Xiaohui Zhou
Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, People’s Republic of China
3 shared publications - Emmanuel Delali Kofi Fiagbey
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, Jiangsu, China; Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing 211166, Jiangsu, China
2 shared publications - Ashna Asim
Department of Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, Jiangsu, China
1 shared publication Brian Roy Ogony
Department of Pharmacy, China Pharmaceutical University, Nanjing 211198, Jiangsu, China
1 shared publicationEdwin Sospeter Ndoli
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, Jiangsu, China; Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing 211166, Jiangsu, China
1 shared publication- Etima Jeremiah Iweh
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, Jiangsu, China; Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing 211166, Jiangsu, China
1 shared publication
Latest Publications
- Open Access
- 17 June 2026
- Published by Open Exploration Publishing in Exploration of Cardiology
- Vol. 4
Prediction of low cardiac output syndrome in patients following non-isolated coronary artery bypass grafting surgery using machine learning
Aim: Low cardiac output syndrome (LCOS) may be improvable; hence, timely detection and intervention are essential. However, no model has been established for the prediction of LCOS onset post non-isolated coronary artery bypass grafting (CABG) surgery. Therefore, this study aimed to develop a machine-learning-based model to predict LCOS after non-isolated CABG. Methods: A total of 378 patients who underwent non-isolated CABG at Nanjing First Hospital, China, were retrospectively assessed. Five algorithms [L2 regularized logistic regression (LR), random forest (RF) classifier, extreme gradient boosting (XGB), light gradient boosting machine (LGBM), and support vector machine (SVM)] were employed. Model performance and clinical utility were evaluated using area under the curve (AUC), 10-fold cross-validation, and decision curve analysis (DCA). SHapley Additive exPlanations (SHAP) were used to assess the model’s interpretability. A web calculator was developed. Results: XGB showed superior performance and calibration (AUC: 0.933, 95% CI: 0.903–0.962; Brier score of 0.107), with excellent specificity (0.865), accuracy (0.860), and precision (0.753). In testing, XGB maintained excellent discrimination (AUC: 0.868, 95% CI: 0.799–0.936), best specificity (0.785), accuracy (0.781), and precision (0.614). DCA confirmed clinical usefulness. SHAP analysis identified the ejection fraction, left ventricular end-systolic diameter, and lactate levels as the most influential predictors. The web calculator is accessible via https://lcos-cabg-xgb-model.streamlit.app/ Conclusions: The developed web-based XGB model effectively predicts LCOS after non-isolated CABG, aiding early risk stratification and detection.
- 17 June 2026
- Published by Open Exploration Publishing in Exploration of Cardiology
- Vol. 4
Open AccessPrediction of low cardiac output syndrome in patients following non-isolated coronary artery bypass grafting surgery using machine learning
Aim: Low cardiac output syndrome (LCOS) may be improvable; hence, timely detection and intervention are essential. However, no model has been established for the prediction of LCOS onset post non-isolated coronary artery bypass grafting (CABG) surgery. Therefore, this study aimed to develop a machine-learning-based model to predict LCOS after non-isolated CABG. Methods: A total of 378 patients who underwent non-isolated CABG at Nanjing First Hospital, China, were retrospectively assessed. Five algorithms [L2 regularized logistic regression (LR), random forest (RF) classifier, extreme gradient boosting (XGB), light gradient boosting machine (LGBM), and support vector machine (SVM)] were employed. Model performance and clinical utility were evaluated using area under the curve (AUC), 10-fold cross-validation, and decision curve analysis (DCA). SHapley Additive exPlanations (SHAP) were used to assess the model’s interpretability. A web calculator was developed. Results: XGB showed superior performance and calibration (AUC: 0.933, 95% CI: 0.903–0.962; Brier score of 0.107), with excellent specificity (0.865), accuracy (0.860), and precision (0.753). In testing, XGB maintained excellent discrimination (AUC: 0.868, 95% CI: 0.799–0.936), best specificity (0.785), accuracy (0.781), and precision (0.614). DCA confirmed clinical usefulness. SHAP analysis identified the ejection fraction, left ventricular end-systolic diameter, and lactate levels as the most influential predictors. The web calculator is accessible via https://lcos-cabg-xgb-model.streamlit.app/ Conclusions: The developed web-based XGB model effectively predicts LCOS after non-isolated CABG, aiding early risk stratification and detection.
- Open Access
- 16 April 2026
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 6, 1003247
The autophagy-exosome axis in chronic prostatitis/chronic pelvic pain syndrome: a hypothesis-driven narrative review
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a debilitating condition of the urogenital system, with an elusive and multifactorial pathogenesis. Recent data show that there is a potential interplay between dysregulated autophagy and altered exosomal communication that may contribute to the persistent inflammation and pain characteristic of CP/CPPS. This review synthesizes recent advances to propose a hypothetical model: cellular stress in the prostate may trigger dysfunctional autophagy, which could reprogram secreted exosomes biogenesis and cargo in a series of lipid-raft microdomain-involved mechanisms and secretory autophagy. The outcomes of this process include the release of pro-inflammatory cytokines (e.g., IL-1β, TNF-α) enriched exosomes, damage-associated molecular patterns (DAMPs), microRNAs (e.g., miR-155), and fibrotic mediators (e.g., TGF-β1). These signalosomes are hypothesized to transmit the inflammatory and nociceptive signals and may contribute to coordinating the dysregulation of immune cells (such as the M1 polarization of macrophages), sensitization of neurons, and tissue fibrosis, thereby potentially perpetuating the presence of a chronic disease. We critically assess the available evidence based on human studies, animal models, and in vitro systems, but recognize that there is a present requirement for additional CP/CPPS-specific mechanistic evidence. Furthermore, we explore the translational implications of this axis, discussing its promise for yielding novel exosome-based diagnostic biomarkers and its potential as a therapeutic target, while also highlighting the significant preclinical challenges and risks that must be overcome. Ultimately, the autophagy-exosome axis presents a new, integrative concept of CP/CPPS, which shifts the paradigm to the mechanisms of intercellular communication and provides new possibilities to carry out mechanism-selective research and future treatment options.
- 16 April 2026
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 6, 1003247
Open AccessThe autophagy-exosome axis in chronic prostatitis/chronic pelvic pain syndrome: a hypothesis-driven narrative review
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a debilitating condition of the urogenital system, with an elusive and multifactorial pathogenesis. Recent data show that there is a potential interplay between dysregulated autophagy and altered exosomal communication that may contribute to the persistent inflammation and pain characteristic of CP/CPPS. This review synthesizes recent advances to propose a hypothetical model: cellular stress in the prostate may trigger dysfunctional autophagy, which could reprogram secreted exosomes biogenesis and cargo in a series of lipid-raft microdomain-involved mechanisms and secretory autophagy. The outcomes of this process include the release of pro-inflammatory cytokines (e.g., IL-1β, TNF-α) enriched exosomes, damage-associated molecular patterns (DAMPs), microRNAs (e.g., miR-155), and fibrotic mediators (e.g., TGF-β1). These signalosomes are hypothesized to transmit the inflammatory and nociceptive signals and may contribute to coordinating the dysregulation of immune cells (such as the M1 polarization of macrophages), sensitization of neurons, and tissue fibrosis, thereby potentially perpetuating the presence of a chronic disease. We critically assess the available evidence based on human studies, animal models, and in vitro systems, but recognize that there is a present requirement for additional CP/CPPS-specific mechanistic evidence. Furthermore, we explore the translational implications of this axis, discussing its promise for yielding novel exosome-based diagnostic biomarkers and its potential as a therapeutic target, while also highlighting the significant preclinical challenges and risks that must be overcome. Ultimately, the autophagy-exosome axis presents a new, integrative concept of CP/CPPS, which shifts the paradigm to the mechanisms of intercellular communication and provides new possibilities to carry out mechanism-selective research and future treatment options.
- 26 February 2026
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1) , 203
The exosome-autophagy axis: emerging mechanisms and therapeutic implications in type III prostatitis
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) is characterized by chronic pelvic pain and urinary symptoms that imposes a significant quality-of-life burden, but the pathogenesis of this syndrome is poorly known, preventing effective therapy. Exosomes, small extracellular vesicles, which mediate cellular communication through proteins, cytokines, and miRNAs, are potent immune modulators that promote prostate inflammation and fibrosis. Simultaneously, dysregulated autophagy, a conserved degradation pathway essential for cellular homeostasis, is involved in the chronic inflammation and immune dysfunction characteristic of CP/CPPS. Critically, emerging evidence points to a bidirectional, functional crosstalk between exosome secretion and autophagic flux. This review proposes and critically evaluates the hypothesis that this ‘exosome-autophagy axis’ is a self-perpetuating process that contributes to immune dysregulation, neuroinflammation and tissue remodelling in CP/CPPS. We synthesize the limited direct data of the CP/CPPS with information extrapolated based on related conditions, establish particular cellular discussions that may operationalize this axis, and discuss its potential implications for future biomarker and therapeutic strategies. Graphical Abstract
- 26 February 2026
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1) , 203
The exosome-autophagy axis: emerging mechanisms and therapeutic implications in type III prostatitis
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) is characterized by chronic pelvic pain and urinary symptoms that imposes a significant quality-of-life burden, but the pathogenesis of this syndrome is poorly known, preventing effective therapy. Exosomes, small extracellular vesicles, which mediate cellular communication through proteins, cytokines, and miRNAs, are potent immune modulators that promote prostate inflammation and fibrosis. Simultaneously, dysregulated autophagy, a conserved degradation pathway essential for cellular homeostasis, is involved in the chronic inflammation and immune dysfunction characteristic of CP/CPPS. Critically, emerging evidence points to a bidirectional, functional crosstalk between exosome secretion and autophagic flux. This review proposes and critically evaluates the hypothesis that this ‘exosome-autophagy axis’ is a self-perpetuating process that contributes to immune dysregulation, neuroinflammation and tissue remodelling in CP/CPPS. We synthesize the limited direct data of the CP/CPPS with information extrapolated based on related conditions, establish particular cellular discussions that may operationalize this axis, and discuss its potential implications for future biomarker and therapeutic strategies. Graphical Abstract
- Open Access
- 9 January 2026
- Published by Open Exploration Publishing in Exploration of Drug Science
- Vol. 4, 1008141
Innovative immunotherapies for prostate cancer: understanding the synergies between checkpoint inhibition, CAR T-cell therapy, and next-generation therapeutic modalities
Immunotherapy has transformed oncology, yet has only been marginally effective in prostate cancer (PCa), which is a malignancy with a low mutational load and a highly immunosuppressive tumor microenvironment (TME). This critical review is a reflection on the changing position of the innovative immunotherapies in PCa that extends beyond the description stage to synthesize the synergies and constraints of immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapy, and next-generation modalities such as bispecific T-cell engagers (BiTEs). We assess the mechanistic reasoning of combination therapies, comprising androgen receptor signaling communicators, PARP communicators, and radioligand therapies, which seek to modulate the immunogenicity of the immune-cold PCa TME. Also, we combine new knowledge to novel resistance pathways, including the newly discovered thrombospondin-1-CD47 axis, in the process of T cell exhaustion through calcineurin-NFAT signaling. Although some preclinical data and initial clinical indicators in biomarker-selected subpopulations are promising, the vast majority of Phase III trials of ICIs in unselected populations with metastatic castration-resistant prostate cancer (mCRPC) have failed. This review reveals that the next generation of PCa immunotherapy would not be sequential monotherapies but rather rationally designed multimodal combinations guided by profound molecular and immune profiling to overcome inherent resistance mechanisms.
- 9 January 2026
- Published by Open Exploration Publishing in Exploration of Drug Science
- Vol. 4, 1008141
Open AccessInnovative immunotherapies for prostate cancer: understanding the synergies between checkpoint inhibition, CAR T-cell therapy, and next-generation therapeutic modalities
Immunotherapy has transformed oncology, yet has only been marginally effective in prostate cancer (PCa), which is a malignancy with a low mutational load and a highly immunosuppressive tumor microenvironment (TME). This critical review is a reflection on the changing position of the innovative immunotherapies in PCa that extends beyond the description stage to synthesize the synergies and constraints of immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapy, and next-generation modalities such as bispecific T-cell engagers (BiTEs). We assess the mechanistic reasoning of combination therapies, comprising androgen receptor signaling communicators, PARP communicators, and radioligand therapies, which seek to modulate the immunogenicity of the immune-cold PCa TME. Also, we combine new knowledge to novel resistance pathways, including the newly discovered thrombospondin-1-CD47 axis, in the process of T cell exhaustion through calcineurin-NFAT signaling. Although some preclinical data and initial clinical indicators in biomarker-selected subpopulations are promising, the vast majority of Phase III trials of ICIs in unselected populations with metastatic castration-resistant prostate cancer (mCRPC) have failed. This review reveals that the next generation of PCa immunotherapy would not be sequential monotherapies but rather rationally designed multimodal combinations guided by profound molecular and immune profiling to overcome inherent resistance mechanisms.